222 related articles for article (PubMed ID: 33297779)
1. Biomarkers for acute and chronic graft versus host disease: state of the art.
Giaccone L; Faraci DG; Butera S; Lia G; Di Vito C; Gabrielli G; Cerrano M; Mariotti J; Dellacasa C; Felicetti F; Brignardello E; Mavilio D; Bruno B
Expert Rev Hematol; 2021 Jan; 14(1):79-96. PubMed ID: 33297779
[TBL] [Abstract][Full Text] [Related]
2. Application of proteomics to graft-versus-host disease: from biomarker discovery to potential clinical applications.
Presland RB
Expert Rev Proteomics; 2017 Nov; 14(11):997-1006. PubMed ID: 28974115
[TBL] [Abstract][Full Text] [Related]
3. Review of Genetic Variation as a Predictive Biomarker for Chronic Graft-Versus-Host-Disease After Allogeneic Stem Cell Transplantation.
Partanen J; Hyvärinen K; Bickeböller H; Bogunia-Kubik K; Crossland RE; Ivanova M; Perutelli F; Dressel R
Front Immunol; 2020; 11():575492. PubMed ID: 33193367
[TBL] [Abstract][Full Text] [Related]
4. New therapeutic targets and biomarkers for acute graft-versus-host disease (GVHD).
Choe H; Ferrara JLM
Expert Opin Ther Targets; 2021 Sep; 25(9):761-771. PubMed ID: 34669521
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease biomarkers: omics and personalized medicine.
Paczesny S; Raiker N; Brooks S; Mumaw C
Int J Hematol; 2013 Sep; 98(3):275-92. PubMed ID: 23959582
[TBL] [Abstract][Full Text] [Related]
6. Role of cytokines in the pathophysiology of acute graft-versus-host disease (GVHD): are serum/plasma cytokines potential biomarkers for diagnosis of acute GVHD following allogeneic hematopoietic cell transplantation (Allo-HCT)?
Toubai T; Tanaka J; Paczesny S; Shono Y; Reddy P; Imamura M
Curr Stem Cell Res Ther; 2012 May; 7(3):229-39. PubMed ID: 22023620
[TBL] [Abstract][Full Text] [Related]
7. Plasma biomarkers in graft-versus-host disease: a new era?
Paczesny S; Levine JE; Braun TM; Ferrara JL
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):33-8. PubMed ID: 19147075
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for acute and chronic graft-versus-host disease in regulatory T cells.
Ukena SN; Geffers R; Buchholz S; Stadler M; Franzke A
Transpl Immunol; 2012 Dec; 27(4):179-83. PubMed ID: 22889700
[TBL] [Abstract][Full Text] [Related]
9. Discovery and validation of graft-versus-host disease biomarkers.
Paczesny S
Blood; 2013 Jan; 121(4):585-94. PubMed ID: 23165480
[TBL] [Abstract][Full Text] [Related]
10. Potential Novel Biomarkers in Chronic Graft-Versus-Host Disease.
Crossland RE; Perutelli F; Bogunia-Kubik K; Mooney N; Milutin Gašperov N; Pučić-Baković M; Greinix H; Weber D; Holler E; Pulanić D; Wolff D; Dickinson AM; Inngjerdingen M; Grce M
Front Immunol; 2020; 11():602547. PubMed ID: 33424849
[TBL] [Abstract][Full Text] [Related]
11. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
12. Prediction of graft-versus-host disease: a biomarker panel based on lymphocytes and cytokines.
Budde H; Papert S; Maas JH; Reichardt HM; Wulf G; Hasenkamp J; Riggert J; Legler TJ
Ann Hematol; 2017 Jul; 96(7):1127-1133. PubMed ID: 28447161
[TBL] [Abstract][Full Text] [Related]
13. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study.
Levine JE; Braun TM; Harris AC; Holler E; Taylor A; Miller H; Magenau J; Weisdorf DJ; Ho VT; Bolaños-Meade J; Alousi AM; Ferrara JL;
Lancet Haematol; 2015 Jan; 2(1):e21-9. PubMed ID: 26687425
[TBL] [Abstract][Full Text] [Related]
14. Proteomics for hematopoietic stem cell transplantation.
Weissinger EM; Basílio-Queirós D; Metzger J; Bieling LM; Ganser A
Expert Rev Proteomics; 2020 Mar; 17(3):201-206. PubMed ID: 32228239
[No Abstract] [Full Text] [Related]
15. The Role of Biomarkers in the Diagnosis and Risk Stratification of Acute Graft-versus-Host Disease: A Systematic Review.
Ali AM; DiPersio JF; Schroeder MA
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1552-1564. PubMed ID: 27158050
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications for biomarkers of acute and chronic graft-versus-host disease.
Levine JE; Paczesny S; Sarantopoulos S
Biol Blood Marrow Transplant; 2012 Jan; 18(1 Suppl):S116-24. PubMed ID: 22226094
[TBL] [Abstract][Full Text] [Related]
17. Blockade of TIM-1 on the donor graft ameliorates graft-versus-host disease following hematopoietic cell transplantation.
Iliopoulou BP; Hsu K; Pérez-Cruz M; Tang SW; Pang WW; Erkers T; Kambham N; Freeman GJ; Dekruyff RH; Meyer EH
Blood Adv; 2019 Nov; 3(21):3419-3431. PubMed ID: 31714958
[TBL] [Abstract][Full Text] [Related]
18. Acute graft-vs-host disease: pathobiology and management.
Goker H; Haznedaroglu IC; Chao NJ
Exp Hematol; 2001 Mar; 29(3):259-77. PubMed ID: 11274753
[TBL] [Abstract][Full Text] [Related]
19. Unlocking protein-based biomarker potential for graft-versus-host disease following allogenic hematopoietic stem cell transplants.
Iacobescu M; Pop C; Uifălean A; Mogoşan C; Cenariu D; Zdrenghea M; Tănase A; Bergthorsson JT; Greiff V; Cenariu M; Iuga CA; Tomuleasa C; Tătaru D
Front Immunol; 2024; 15():1327035. PubMed ID: 38433830
[TBL] [Abstract][Full Text] [Related]
20. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
